Recent FDA Approvals in Hematology and Oncology

Recent FDA Approvals in Hematology and Oncology

The goal of this program is to improve the diagnosis and management of hematologic or solid tumor malignancies. After hearing and assimilating this program, the clinician will be better able to: 1. Administer imetelstat to patients with lower-risk myelodysplastic syndrome when indicated. 2. Explain the mechanism of action of exagamglogene autotemcel. 3. Optimize use of axatilimab in patients with chronic graft vs host disease.

  • Provider:Lippincott Continuing Medical Education Institute, Inc.
  • Activity Link: https://www.audio-digest.org/Specialties/Oncology
  • Start Date: 2024-12-04 06:00:00
  • End Date: 2024-12-04 06:00:00
  • Credit Details: AMA PRA Category 1 Credit™️: 1.75 hours
  • MOC Credit Details: ABIM - 1.75 Point; Credit Type(s): Medical Knowledge (ABIM)
  • Commercial Support: No
  • Activity Type: Enduring Material
  • CME Finder Type: Online Learning
  • Fee to Participate: Yes
  • Measured Outcome: Learner Competence, Learner Knowledge, Learner Performance
  • Provider Ship: Jointly Provided
  • Registration: Open to all
  • Specialty: Medical Oncology
«
»
Subscribe
Notify of
guest
0 Comments
Oldest
Newest Most Voted
Inline Feedbacks
View all comments
0
Would love your thoughts, please comment.x
()
x

Contact us

If you want to join leaders who will shape what Americans think about sleep.

Name(Required)
Sign Up
This field is for validation purposes and should be left unchanged.

Sign up for the expert list

for media inquiries

Name(Required)
Sign Up
This field is for validation purposes and should be left unchanged.